糖尿病性黄斑浮腫(Diabetic Macular Edema)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Macular Edema Overview 8
Therapeutics Development 9
Pipeline Products for Diabetic Macular Edema – Overview 9
Pipeline Products for Diabetic Macular Edema – Comparative Analysis 10
Diabetic Macular Edema – Therapeutics under Development by Companies 11
Diabetic Macular Edema – Therapeutics under Investigation by Universities/Institutes 15
Diabetic Macular Edema – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Diabetic Macular Edema – Products under Development by Companies 20
Diabetic Macular Edema – Products under Investigation by Universities/Institutes 23
Diabetic Macular Edema – Companies Involved in Therapeutics Development 24
ActiveSite Pharmaceuticals, Inc. 24
Acucela Inc. 25
Aerpio Therapeutics, Inc. 26
Alcon, Inc. 27
Allergan, Inc. 28
AlphaMab Co., Ltd 29
Ampio Pharmaceuticals, Inc. 30
Astellas Pharma Inc. 31
Auven Therapeutics Management L.L.L.P 32
Avalanche Biotechnologies, Inc. 33
Eleven Biotherapeutics Inc. 34
F. Hoffmann-La Roche Ltd. 35
Foamix Pharmaceuticals Ltd. 36
Gene Signal International SA 37
Genmab A/S 38
GlaxoSmithKline plc 39
Icon Bioscience, Inc. 40
Kala Pharmaceuticals, Inc. 41
Kowa Company, Ltd. 42
Mabion SA 43
MacuCLEAR, Inc. 44
Molecular Design International, Inc. 45
NicOx S.A. 46
Ohr Pharmaceutical Inc. 47
Pfizer Inc. 48
Quark Pharmaceuticals, Inc. 49
Regeneron Pharmaceuticals, Inc. 50
Santen Pharmaceutical Co., Ltd. 51
SciFluor Life Sciences, LLC 52
Senju Pharmaceutical Co., Ltd. 53
ThromboGenics NV 54
Diabetic Macular Edema – Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Target 56
Assessment by Mechanism of Action 58
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
49-B – Drug Profile 64
abicipar pegol – Drug Profile 66
aganirsen – Drug Profile 68
AKB-9778 – Drug Profile 70
ALG-1001 – Drug Profile 72
Antibodies to Inhibit Hemopexin for Diabetic Macular Edema – Drug Profile 74
ASP-440 – Drug Profile 75
ASP-8232 – Drug Profile 77
AVA-101 – Drug Profile 78
conbercept – Drug Profile 80
danazol – Drug Profile 82
darapladib – Drug Profile 83
dexamethasone acetate nanoparticle – Drug Profile 85
dexamethasone dipropionate – Drug Profile 87
difluprednate – Drug Profile 88
Drug for Diabetic Macular Edema – Drug Profile 89
Drugs to Inhibit Tyrosine Kinase for Ophthalmology – Drug Profile 90
EBI-029 – Drug Profile 91
EBI-031 – Drug Profile 92
emixustat hydrochloride – Drug Profile 93
KVD-001 – Drug Profile 95
LKA-651 – Drug Profile 96
loteprednol etabonate – Drug Profile 97
MC-4001 – Drug Profile 98
minocycline Gel – Drug Profile 99
MTP-131 – Drug Profile 100
NCX-422 – Drug Profile 102
NCX-434 – Drug Profile 103
nesvacumab – Drug Profile 104
ocriplasmin (recombinant) – Drug Profile 106
Peptide for Diabetic Macular Edema – Drug Profile 109
PF-04634817 – Drug Profile 110
PF-655 – Drug Profile 111
ranibizumab – Drug Profile 113
ranibizumab biosimilar – Drug Profile 116
ranibizumab biosimilar – Drug Profile 117
ripasudil – Drug Profile 118
RX-10045 – Drug Profile 119
SF-0166 – Drug Profile 121
Small Molecule to Inhibit Kallikrein for AMD and DME – Drug Profile 122
Small Molecules to Inhibit Plasma Kallikrein for DME and HAE – Drug Profile 123
Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema – Drug Profile 125
squalamine lactate – Drug Profile 126
teprotumumab – Drug Profile 129
Diabetic Macular Edema – Recent Pipeline Updates 132
Diabetic Macular Edema – Dormant Projects 162
Diabetic Macular Edema – Discontinued Products 164
Diabetic Macular Edema – Product Development Milestones 165
Featured News & Press Releases 165
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 174
Disclaimer 174